Financing led by DreamCIS will accelerate and expand development of the company's industry-leading integrated platform, combining human iPSC-derived cells, advanced biosystems, and functional data ...

PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data presentations in support of its preclinical drug ...

Upstream Bio, Inc. presented data at the European Academy of Allergy & Clinical Immunology Congress highlighting the advantages of verekitug, a treatment targeting the TSLP receptor, over tezepelumab, ...

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that updated clinical data on its investigational therapy, ...

CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership.

Researchers can now order their mutation of choice in bit.bio’s opti-ox TM powered human-iPSC derived cells, receiving consistent, defined, cryopreserved products that can be immediately incorporated ...

“High quality, large-scale, fit-for-purpose datasets” continues to be the tagline for artificial intelligence (AI) models aiming to achieve scalable drug discovery to novel targets. While troves of ...